View Older Stories View More Recent Stories

Nov 15, 2020 06:00PM Mirum Pharmaceuticals Announces Data Presented During AASLD Highlighting Durable Improvements in Pruritus and Quality of Life in Children with Alagille Syndrome Treated with Maralixibat
Nov 13, 2020 08:10AM Mirum Pharmaceuticals Presents New Data From Its Maralixibat and Volixibat Clinical Studies at AASLD Annual Meeting
Nov 12, 2020 09:00AM Mirum Pharmaceuticals Provides Third Quarter 2020 Financial Results and Business Update, and Announces Virtual Investor Day
Nov 10, 2020 07:00PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 5, 2020 08:30AM Mirum Pharmaceuticals Broadens Expanded Access Program for Maralixibat in Alagille Syndrome to Europe and Australia
Nov 2, 2020 08:33AM Mirum Pharmaceuticals (MIRM) Announces New Data Being Presented in Late-Breaker Oral and Poster Presentations at AASLD
Nov 2, 2020 08:30AM Mirum Pharmaceuticals Announces New Data Being Presented in Late-Breaker Oral and Poster Presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Oct 26, 2020 08:30AM Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the NASPGHAN Annual Meeting 2020
Oct 15, 2020 08:55AM Mirum Pharmaceuticals Announces Partnership With EVERSANA to Support Launch and Commercialization of Maralixibat for Alagille Syndrome in the United States
Oct 15, 2020 08:47AM Mirum Pharmaceuticals, Inc. (MIRM) Announces Partnership With EVERSANA to Support Launch and Commercialization of Maralixibat for Alagille Syndrome in U.S.
Oct 15, 2020 08:45AM Mirum Pharmaceuticals Announces Partnership With EVERSANA to Support Launch and Commercialization of Maralixibat for Alagille Syndrome in the United States
Oct 13, 2020 04:05PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 11, 2020 04:30PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 11, 2020 07:00AM Mirum Pharmaceuticals to Present at Investor Conferences in September
Sep 1, 2020 09:05AM Mirum Pharmaceuticals (MIRM) Initiates Rolling Submission of NDA for Maralixibat for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome and Launches Expanded Access Program
Sep 1, 2020 09:00AM Mirum Pharmaceuticals Initiates Rolling Submission of a New Drug Application for Maralixibat for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome and Launches Expanded Access P
Aug 29, 2020 08:45AM Mirum Pharmaceuticals Presents Maralixibat Five-Year Transplant-Free Survival Data for Patients With PFIC2 at Digital International Liver Congress 2020
Aug 11, 2020 05:30PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 7, 2020 04:05PM Mirum Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference
Aug 6, 2020 04:05PM Mirum Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Clinical Program Updates
Jul 10, 2020 05:00PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 11, 2020 04:10PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 2, 2020 08:30AM Mirum’s Maralixibat Demonstrates Transplant-Free Survival for Pediatric Patients with Progressive Familial Intrahepatic Cholestasis
May 29, 2020 10:05AM Mirum Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference
May 11, 2020 05:01PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 7, 2020 04:05PM Mirum Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Updates
Apr 28, 2020 04:19PM Mirum Pharmaceuticals Appoints Peter Radovich as Chief Operating Officer
Mar 12, 2020 04:02PM Mirum Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Feb 18, 2020 04:01PM Mirum Pharmaceuticals to Participate at Four Upcoming Conferences
Jan 14, 2020 09:01AM Mirum Pharmaceuticals, Inc. (MIRM) Announces Promotion of Ian Clements to CFO Position
Jan 14, 2020 09:00AM Mirum Pharmaceuticals Promotes Ian Clements to Chief Financial Officer
Dec 16, 2019 08:03AM Mirum Pharmaceuticals, Inc. (MIRM) Completes Successful Pre-NDA Meeting with FDA for Maralixibat
Dec 16, 2019 08:00AM Mirum Pharmaceuticals Completes Successful Pre-NDA Meeting with FDA for Maralixibat
Dec 13, 2019 04:30PM Mirum Pharmaceuticals, Inc. (MIRM) to Provide Regulatory Update in Upcoming Conference Call and Webcast
Dec 13, 2019 04:28PM Mirum Pharmaceuticals to Provide Regulatory Update in Upcoming Conference Call and Webcast
Nov 25, 2019 08:30AM Mirum Pharmaceuticals to Present at Evercore ISI 2nd Annual HealthCONx Conference
Nov 8, 2019 08:08AM Mirum Pharmaceuticals, Inc. (MIRM) Presents Data Demonstrating Long-term Durability of Treatment Effect of Maralixibat in Children With Cholestatic Liver Disease
Nov 8, 2019 08:05AM Mirum Pharmaceuticals Presents Data Demonstrating Long-term Durability of Treatment Effect of Maralixibat in Children With Cholestatic Liver Diseases
Nov 6, 2019 04:05PM Mirum Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update
Oct 28, 2019 04:05PM Mirum Pharmaceuticals Announces Appointment of Ed Tucker as Chief Medical Officer
Oct 28, 2019 08:35AM Mirum Pharmaceuticals, Inc. (MIRM) Granted Breakthrough Therapy Designation for Maralixibat for the Treatment of Pruritus Associated with Alagille Syndrome
Oct 28, 2019 08:30AM Mirum Pharmaceuticals Announces Breakthrough Therapy Designation for Maralixibat for the Treatment of Pruritus Associated with Alagille Syndrome
Oct 21, 2019 10:15AM Durability of Treatment Effect of Mirum Pharmaceuticals’ Maralixibat for Children With Alagille Syndrome Featured in Late Breaking Session at the Liver Meeting 2019
Oct 1, 2019 04:30PM Mirum Pharmaceuticals to Present New Data at The Liver Meeting 2019
Sep 26, 2019 08:30AM Mirum Pharmaceuticals to Present at Cantor 2019 Global Healthcare Conference
Aug 28, 2019 04:01PM Mirum Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update
View More Recent Stories View Older Stories